epiCapture Prostate Cancer Test

Understanding the risk of aggressive cancer

EpiCapture analyses subtle changes in DNA that are linked to cancer behaviour. By combining this information with other clinical and personal data, it provides a personalised risk score for the likelihood of developing more aggressive prostate cancer.

A non-invasive alternative

The test uses a simple urine sample—avoiding the discomfort and risks of needle biopsy and reducing reliance on costly MRI imaging.

Supporting better decisions

With clearer information about cancer risks, patients and clinicians can make more informed decisions about monitoring and treatment—potentially reducing unnecessary procedures.

Designed to improve quality of life

Prostate cancer affects around 1 in 8 men. EpiCapture is designed to help minimise stress, discomfort, and uncertainty by offering a more convenient and patient-friendly approach to ongoing monitoring.